Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 66   

Articles published

GSK 1,534.50
price chart
GlaxoSmithKline Leads Borrowers Selling Most Debt Since March
May 2 (Bloomberg) -- GlaxoSmithKline Plc, the U.K.'s largest drugmaker, sold $5 billion of bonds in its first dollar-denominated offering in four years as companies market the most U.S.
Related articles »  
Glaxo to Begin Hostile Offer for Human Genome Sciences
May 9 (Bloomberg) -- GlaxoSmithKline Plc will begin a hostile $2.6 billion tender offer this week for Human Genome Sciences Inc. after the U.S.
Related articles »  
Glaxo Scientist, Surgeon Targeting Historic British Hockey Gold
MacLeod, 27, also worked for GlaxoSmithKline Plc, the U.K.'s biggest drugmaker, as a sports scientist on its Lucozade energy drink.
Related articles »  
Glaxo's Melanoma Cocktail Slows Cancer in Study
May 17 (Bloomberg) -- GlaxoSmithKline Plc's combination of two experimental melanoma medicines slowed the progress of cancer with few skin complications in an early study, suggesting the combo may not have as many side effects as existing single-drug ...
Dabrafenib And Trametinib: Melanoma Drug Combo Shows Promise In Small Trial  Huffington Post
Related articles »  
Stock to Watch: Telecom Plus
This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall.
GlaxoSmithKline Launches Hostile Takeover Bid for Human Genome Sciences
GlaxoSmithKline Plc (NYSE: GSK), Britain's biggest drugmaker, will mount a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (NASDAQ: HGSI), the company announced Wednesday.
Related articles »  
Glaxo Diabetes Drug Data Revealed Amid Hostile Takeover
May 25 (Bloomberg) -- GlaxoSmithKline Plc will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc., its partner on the drug.
Related articles »  
Glaxo's Stiefel Unit Loses $1.5 Million Verdict on Buybacks
May 18 (Bloomberg) -- Stiefel Laboratories lost a $1.5 million jury verdict to a former employee who claimed the company bought back his stock at artificially low prices before its acquisition in 2009 by GlaxoSmithKline Plc. Timothy Finnerty won the ...
Related articles »  
GlaxoSmithKline: Complied With Indian Rules for Drug Approval
BANGALORE - GlaxoSmithKline GSK -0.40 % PLC said Thursday it was granted a waiver on conducting clinical trials in India for ambrisentan, its drug to treat pulmonary arterial hypertension, as local rules allow such a concession for drugs treating a ...
Indian Drug Regulator Accused of Corruption and Collusion  Bloomberg
Related articles »  
Human Genome in Talks With Potential Suitors
May 17 (Bloomberg) -- Human Genome Sciences Inc. said it's in talks with �major� pharmaceutical and biotechnology companies about a potential transaction and adopted measures to avoid a hostile takeover by GlaxoSmithKline Plc. Human Genome ...
Related articles »